Goldman Sachs Starts Cubist Pharmaceuticals (CBST) at Conviction Buy, Sees 24% Upside
Tweet
Share
E-mail
Get Alerts CBST Hot Sheet
Price: $101.94 --0%
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs initiates coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Conviction Buy List rating and $54 price target, suggesting 24% upside.
The firm highlight that Cubist is a profitable mid-cap biotechnology company with two marketed drugs ($925mn 2012E revenue) and a late-stage pipeline (three drugs in Phase 3, Ph3, by YE2012).
"In our view, the key driver of shares is pipeline drug CXA for hospital-acquired infections, for which we expect positive Ph3 data in 2H13. We project that CXA’s
expected launch in 2H14 will help drive outer-year growth (we model 2013-
2016E EPS CAGR of 20%)," the analyst comments.
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $43.49 yesterday.
The firm highlight that Cubist is a profitable mid-cap biotechnology company with two marketed drugs ($925mn 2012E revenue) and a late-stage pipeline (three drugs in Phase 3, Ph3, by YE2012).
"In our view, the key driver of shares is pipeline drug CXA for hospital-acquired infections, for which we expect positive Ph3 data in 2H13. We project that CXA’s
expected launch in 2H14 will help drive outer-year growth (we model 2013-
2016E EPS CAGR of 20%)," the analyst comments.
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $43.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- JPMorgan Resumes SanDisk (SNDK) at Overweight
- Canaccord Starts Galiano Gold (GAU:CN) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
